Pharmaceutical

Hoth and Aronnax partner for HT-KIT cancer therapy development

Hoth Therapeutics has announced a master services agreement with Aronnax to advance the development of its HT-KIT cancer therapeutic.

Aug 17, 2024 - 04:00
Hoth and Aronnax partner for HT-KIT cancer therapy development
Hoth Therapeutics has announced a master services agreement with Aronnax to advance the development of its HT-KIT cancer therapeutic.
Read the original article

Tags:

Previous Article

Lykos cuts team by 75%, vows to keep MDMA program despite FDA veto

Next Article

FDA accepts Deciphera’s vimseltinib NDA for priority review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers

STAT+: FTC move to block the Amgen-Horizon deal highlig...

May 17, 2023

Pacira BioSciences gets grant for method for treating s...

May 1, 2024

Singapore startup Albatroz wins financing to develop solid tumour drugs

Singapore startup Albatroz wins financing to develop so...

Apr 26, 2023